表紙
市場調查報告書
商品編碼
808281

歐洲的Glucagon-Like Peptide-1(GLP-1)促效劑市場 - 成長,趨勢,預測(2019年∼2024年)

EUROPE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 80 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

歐洲的Glucagon-Like Peptide-1(GLP-1)促效劑市場受到新藥上市的影響,從2019年到2024年間,預測將以14.5%的年複合成長率發展,並記錄驚異性的成長。

本報告提供歐洲的Glucagon-Like Peptide-1(GLP-1)促效劑市場調查,市場概要,各市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各類醫藥品
    • Exenatide
    • 利拉魯肽
    • Lixisenatide
    • Dulaglutide
  • 各地區
    • 歐洲
      • 德國
      • 西班牙
      • 義大利
      • 法國
      • 英國
      • 俄羅斯
      • 其他

第6章 市場指標

  • 第一型糖尿病人口(實在數值、預測值)
  • 第二型糖尿病人口(實在數值、預測值)

第7章 競爭情形

  • 企業簡介
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • AstraZeneca
  • 市場佔有率分析
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • AstraZeneca

第8章 市場機會及未來趨勢

目錄
Product Code: 62935

The Europe glucagon-like peptide-1 (GLP-1) market is expected to witness tremendous growth during the forecast period (2021- 2026), with a CAGR greater than 15%, mainly as a result of new drug launches. Europe has approximately 57 million adults living with diabetes, and this number is expected to reach 75 million by 2026, which would represent around 10% of the total population of Europe. Europe's expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway. Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal. In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.

Key Market Trends

Ever Increasing Burden of Diabetes in the European Region

The rates of new diagnosed cases of Type 1 and Type 2 diabetes are seen increasing among the youth population in Europe. The prevalence of diabetes among all ages in the European region is increasing, mainly due to obesity, unhealthy diet, and physical inactivity. The prevalence of autoimmune Type 1 diabetes is also increasing in Europe, and as per sources, Europe has the highest number of children with Type 1 diabetes. Though Type 2 patient's treatment is initiated with oral drugs, insulin may also be required when glucose levels are not well controlled, due to the unhealthy lifestyle. Thus, the demand for insulin also exists among Type 2 diabetes patients. It is one of the most common chronic diseases in the United Kingdom. As there is an exponential growth of the diabetes population, year on year, especially of type-2 diabetes, new innovative drugs are emerging in the market, for the ease of access to the patients.

Germany to Dominate the Europe GLP-1 Market

Among the studied countries, Germany is expected to lead the market, with a considerable 27.25% of the market share, followed by France. Victoza holds the highest market share in the European region, and a similar trend is seen in Germany too. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells, suppressing inappropriate elevated glucagon secretion. An estimated 8.03 million citizens suffer from any form of diabetes in the country, which puts the country at high risk, due to the outbreak of COVID-19 in the country. The German Diabetes Society is one of the largest medical-scientific societies in Germany. The organization supports the research and training of medical personnel and develops medical guidelines for the diagnosis of diabetes. According to the German Diabetes Society, about 30,500 children and adolescents under the age of 19 are currently affected by Type 1 diabetes.

Competitive Landscape

The GLP-1 market is consolidated, with four major manufacturers holding a presence in all the regions. The market for GLP-1 agonist drugs includes Victoza, Trulicity, Byetta, Bydureon, and Lyxumia. The market is expected to grow significantly over the forecast period, because of Trulicity and Ozempic. A version of Semaglutide (Rybelsus) which is taken by mouth was approved for medical use in the European Union in April 2020.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug
    • 5.1.1 Exenatide
      • 5.1.1.1 Byetta (Value and Volume 2016 - 2026)
      • 5.1.1.2 Bydureon (Value and Volume 2016 - 2026)
    • 5.1.2 Liraglutide
      • 5.1.2.1 Victoza (Value and Volume 2016 - 2026)
    • 5.1.3 Lixisenatide
      • 5.1.3.1 Lyxumia (Value and Volume 2016 - 2026)
    • 5.1.4 Dulaglutide
      • 5.1.4.1 Trulicity (Value and Volume 2016 - 2026)
  • 5.2 Geography
    • 5.2.1 Europe
      • 5.2.1.1 Germany (Value and Volume 2016 - 2026)
      • 5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.1.2 Spain (Value and Volume 2016 - 2026)
      • 5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.1.3 Italy (Value and Volume 2016 - 2026)
      • 5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.1.4 France (Value and Volume 2016 - 2026)
      • 5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
      • 5.2.1.5 United Kingdom (Value and Volume 2016 - 2026)
      • 5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.1.6 Russia (Value and Volume 2016 - 2026)
      • 5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.1.7 Rest of Europe (Value and Volume 2016 - 2026)
      • 5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2016 - 2026)
  • 6.2 Type-2 Diabetes Population (2016 - 2026)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk
    • 7.1.2 Sanofi
    • 7.1.3 Eli Lilly
    • 7.1.4 AstraZeneca
  • 7.2 MARKET SHARE ANALYSIS
    • 7.2.1 NovoNordisk
    • 7.2.2 Sanofi
    • 7.2.3 Eli Lilly
    • 7.2.4 AstraZeneca

8 MARKET OPPORTUNITIES AND FUTURE TRENDS